CLDN11 and osteosarcoma: In order to develop a risk model with the optimal prognostic predictive capacity of these DE-AAMRGs in osteosarcoma patients, we performed univariate Cox analysis and utilized the LASSO method to select a panel of five biomarkers (CD36, CLDN11, EPYC, PANX3, and STOM) (Fig. 2A and C).